Emerging aspergillosis by azole-resistant aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013

Eurosurveillance

Volumn 21, Issue 30, 2016, Pages

  Van Paassen, J ^a   Russcher, A ^a   In't Veld Van Wingerden A W ^a   Verweij, P E ^b   Kuijper, E J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; MICROSATELLITE DNA; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT; CYTOCHROME P-450 CYP51A, ASPERGILLUS; CYTOCHROME P450; FUNGAL PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHOSCOPY; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; LUNG BIOPSY; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; NETHERLANDS; OUTCOME ASSESSMENT; PREVALENCE; RETROSPECTIVE STUDY; TANDEM REPEAT; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PROGNOSIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENOTYPE; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VORICONAZOLE;

EID: 85015137447     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.30.30300     Document Type: Article

References (32)

1. Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WJG. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9(12):789-95. DOI: 10.1016/S1473-3099(09)70265-8 PMID: 19926038
2. van der Linden JWM, Camps SMT, Kampinga GA, Arends JPA, Debets-Ossenkopp YJ, Haas PJA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57(4):513-20. DOI: 10.1093/cid/cit320 PMID: 23667263
3. van der Linden JWM, Snelders E, Kampinga GA, Rijnders BJA, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011;17(10):1846-54. DOI: 10.3201/eid1710.110226 PMID: 22000354
4. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26(6):493-500. DOI: 10.1097/QCO.0000000000000005 PMID: 24126719
5. Denning DW, Bowyer P. Voriconazole resistance in Aspergillus fumigatus: should we be concerned? Clin Infect Dis. 2013;57(4):521-3. DOI: 10.1093/cid/cit321 PMID: 23667265
6. Steinmann J, Hamprecht A, Vehreschild MJGT, Cornely OA, Buchheidt D, Spiess B, et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015;70(5):1522-6. DOI: 10.1093/jac/dku566 PMID: 25630644
7. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azoleresistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9(10):1003633. DOI: 10.1371/journal.ppat.1003633 PMID: 24204249
8. Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F, Verweij PE, et al. Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. J Antimicrob Chemother. 2014;69(11):2979-83. DOI: 10.1093/jac/dku259 PMID: 25006238
9. Le Pape P, Lavergne RA, Morio F, Alvarez-Moreno C. Multiple Fungicide-Driven Alterations in Azole-Resistant Aspergillus fumigatus, Colombia, 2015. Emerg Infect Dis. 2016;22(1):156-7. DOI: 10.3201/eid2201.150978 PMID: 26690795
10. Wiederhold NP, Gil VG, Gutierrez F, Lindner JR, Albataineh MT, McCarthy DI, et al. First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States. J Clin Microbiol. 2016;54(1):168-71. DOI: 10.1128/JCM.02478-15 PMID: 26491179
11. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45(2):205-16. DOI: 10.1086/518852 PMID: 17578780
12. Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al., AspICU Study Investigators. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19(1):7. DOI: 10.1186/s13054-014-0722-7 PMID: 25928694
13. De Pauw BE. Increasing fungal infections in the intensive care unit. Surg Infect (Larchmt). 2006;7(2):93-6.PMID: 16895517
14. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10(1):31. DOI: 10.1186/cc4823 PMID: 16507158
15. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21. DOI: 10.1086/588660 PMID: 18462102
16. Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186(1):56-64. DOI: 10.1164/rccm.201111-1978OC PMID: 24126719
17. Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of Clinical Microbiology. 10th edition. Washington, DC: ASM Press; 2011.
18. Lass-Flörl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008;52(10):3637-41. DOI: 10.1128/AAC.00662-08 PMID: 18694949
19. de Valk HA, Meis JF, Curfs IM, Muehlethaler K, Mouton JW, Klaassen CH. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol. 2005;43(8):4112-20. DOI: 10.1128/JCM.43.8.4112-4120.2005 PMID: 16081958
20. Fuhren J, Voskuil WS, Boel CH, Haas PJ, Hagen F, Meis JF, et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother. 2015;70(10):2894-8. DOI: 10.1093/jac/dkv177 PMID: 26163402
21. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007;33(10):1694-703. DOI: 10.1007/s00134-007-0791-z PMID: 17646966
22. Snelders E, Huis In’t Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75(12):4053-7. DOI: 10.1128/AEM.00231-09 PMID: 19376899
23. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother. 2012;56(1):10-6. DOI: 10.1128/AAC.05088-11 PMID: 22005994
24. Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. J Antimicrob Chemother. 2015;70(2):412-5. DOI: 10.1093/jac/dku410 PMID:25326091
25. Spiess B, Seifarth W, Merker N, Howard SJ, Reinwald M, Dietz A, et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother. 2012;56(7):3905-10. DOI: 10.1128/AAC.05902-11 PMID: 22526309
26. Chong GLM, van de Sande WW, Dingemans GJH, Gaajetaan GR, Vonk AG, Hayette MP, et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol. 2015;53(3):868-74. DOI: 10.1128/JCM.03216-14 PMID: 25568431
27. White PL, Posso RB, Barnes RA. Analytical and clinical evaluation of the pathoNostics AsperGenius assay for detection of invasive aspergilosis and resistance to azole antifungal drugs during testing of serum samples. J Clin Microbiol. 2015;53(7):2115-21. DOI: 10.1128/JCM.00667-15 PMID: 25903571
28. Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azoleresistant Aspergillus fumigatus. Drug Resist Updat. 2015;21-22:30-40. DOI: 10.1016/j.drup.2015.08.001 PMID: 26282594
29. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2013;57(4):1866-71. DOI: 10.1128/AAC.02226-12 PMID: 23380732
30. Seyedmousavi S, Brüggemann RJM, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Chemother. 2013;68(2):385-93. DOI: 10.1093/jac/dks402 PMID: 23129729
31. Seyedmousavi S, Mouton JW, Melchers WJG, Brüggemann RJM, Verweij PE. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. Drug Resist Updat. 2014;17(3):37-50. DOI: 10.1016/j.drup.2014.06.001 PMID: 25066814
32. Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors’ response. J Antimicrob Chemother. 2015;70(2):634-5. DOI: 10.1093/jac/dku484 PMID: 25488075